Drug Trial Radar · NCT07531095
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 21, 2026
Primary completion
May 21, 2028
Study completion May 21, 2031
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Conditions
- Small Cell Lung Cancer
Interventions
ZL-1310Drug
ZL-1310 will be administered as an IV infusion.
TarlatamabDrug
Tarlatamab will be administered as an IV infusion.
DurvalumabDrug
Durvalumab will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3.5 years
- Parts 1 and 3: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Up to Day 21
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope Cancer Center Phoenix
Goodyear, Arizona · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
City of Hope Chicago
Zion, Illinois · Recruiting
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota · Recruiting
New York University Cancer Institute
New York, New York · Recruiting
Baptist Cancer Center
Memphis, Tennessee · Recruiting
Next Virginia
Fairfax, Virginia · Recruiting
Monash Medical Centre
Clayton, Victoria, Australia · Recruiting
Institut Jules Bordet
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Ziekenhuis aan de Stroom Augustinus
Wilrijk, Belgium · Recruiting
Centre Hospitalier Universitaire de Lyon Hopital Louis Pradel
Bron, France · Recruiting
Hopital de la Timone
Marseille, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitaetsklinikum Dresden
Dresden, Germany · Recruiting
Universitaetsklinikum Wuerzburg
Würzburg, Germany · Recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Recruiting
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Gliwice, Poland · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Clinico Universitario Virgen de la Victoria
Málaga, Andalusia, Spain · Recruiting
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Valencia, Spain · Recruiting
Kantonsspital Sankt Gallen
Sankt Gallen, Switzerland · Recruiting
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, Turkey (Türkiye) · Recruiting
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, Turkey (Türkiye) · Recruiting
Izmir Ekonomi Universitesi Medical Point Hastanesi
Izmir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.